Acceleron Pharma (XLRN) Misses Q1 EPS by 15c, Revenues Miss

Acceleron Pharma (NASDAQ: XLRN) reported Q1 EPS of ($0.74), $0.15 worse than the analyst estimate of ($0.59). Revenue for the quarter came in at $2.78 million versus the consensus estimate of $7.32 million.

“With the submission of marketing applications for luspatercept in the U.S. and E.U. last month, we and our global collaboration partner, Celgene, are excited about the potential to bring a new therapy to patients with myelodysplastic syndromes and beta-thalassemia within the next year,” said Habib Dable, President and Chief Executive Officer of Acceleron. “At the same time, our pulmonary program remains on track, with enrollment ongoing in two Phase 2 trials of sotatercept in PAH, and we are anticipating topline results from the placebo-controlled part of the Phase 2 trial of our locally-acting muscle agent, ACE-083, in FSHD during the second half of this year.”

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Is Treasury selloff a major issue for stock market bulls?
• Rocket Companies adds Sarah Watterson to its board of directors